Table 3.
PASI scores, changes in treatment, and declining antigliadin IgA following introduction of GFD in five selected patients with baseline serum antigliadin IgA >30.0 U/mL
| Response to GFD | Patient A | Patient B | Patient C | Patient D | Patient E |
|---|---|---|---|---|---|
| AGA on recruitment | 38.8 | 93.2 | 56.5 | 120.3 | >142.0 U/mL |
| AGA at 12 mo. of GFD (negative/equivocal = 0.1–11.4) | 9.1 | 7.3 | 5.4 | 10.5 | 14.8 |
| PASI on recruitment | 13.9 | 20.2 | 11.6 | 9.0 | 5.6 |
| PASI at 12 mo. of GFD | 5.0 | 11.6 | 5.9 | 2.4 | 2.1 |
| Decline of PASI | 64% | 43% | 50% | 74% | 63% |
| Methotrexate on recruitment | 7.5 | 10.0 | 7.5 | 0 | 0 |
| Methotrexate at 12 mo. of GFD (mg/wk) | 0 | 5.0 | 0 | 0 | 0 |
| Cyclosporine on recruitment | – | – | – | 4 | – |
| Cyclosporine at 12 mo. of GFD (mg/kg/day) | – | – | – | 0 | – |
| PUVA on recruitment | – | + | + | + | – |
| PUVA at 12 mo. of GFD | – | + | – | – | – |
Note: ‘–’ indicates not applicable.
Abbreviations: PASI, Psoriasis Area and Severity Index; GFD, gluten-free diet; AGA, antigliadin IgA antibody; mo., month(s); PUVA, psoralen plus ultraviolet-A light therapy.